Last reviewed · How we verify

NCT07064538

Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

ENROLLING BY INVITATION NA Last updated 24 August 2025
What this trial tests

NA trial testing Neuralli® MP in ASD in 15 participants. Enrolling by invitation.

Timeline
19 August 2025
Primary endpoint
30 June 2026
31 August 2026

Quick facts

Lead sponsorMackay Memorial Hospital
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment15
Start date19 August 2025
Primary completion30 June 2026
Estimated completion31 August 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

Adults 18 to 50, any sex, with ASD or Autism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of Neuralli® MP in improving participant-defined outcomes in adults with autistic traits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ASD

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07064538.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing